Psychedelics for Mental Health: Research, Regulation, and Therapeutic Potential of Psilocybin

Dr. Tracey Marks discusses the therapeutic potential of psychedelics, particularly psilocybin, for mental health conditions like depression. She explains that psychedelics, including psilocybin, DMT (found in Ayahuasca), mescaline (from peyote cactus), LSD, and MDMA (Ecstasy), primarily activate the serotonin 5HT2a receptor, leading to altered states of consciousness and hallucinatory experiences. While various psychedelics are being studied, psilocybin has emerged as the frontrunner in the push for clinical approval due to its promising research outcomes and the significant number of ongoing trials.

The podcast makes key distinctions regarding the classification and effects of these substances. Ketamine, while psychoactive and used for depression, is not considered a classic psychedelic due to its temporary effects. MDMA has received FDA approval for study in PTSD treatment. A crucial nuance is the regulatory landscape: psilocybin is currently a Schedule I drug, meaning it's illegal for general use and possession, unlike Schedule II drugs (e.g., opioids, ADHD stimulants) which are legal but highly regulated. The process of FDA approval is detailed, highlighting the role of university-led research versus drug company trials and the significance of "breakthrough therapy designation" in fast-tracking approval for promising treatments.

For individuals interested in accessing psychedelic treatments, the only current avenue is participation in clinical trials. Dr. Marks advises listeners to visit clinicaltrials.gov to search for recruiting studies by drug or location, or to check the websites of companies like Usona Institute and Compass Pathways, which are actively pursuing FDA approval. She also provides a practical caution regarding Ayahuasca, noting its monoamine oxidase inhibitor (MAOI) properties and the potential for dangerous food or medication interactions. The complex legal status of cannabis as a Schedule I drug, despite state-level state legalization, is briefly mentioned as a parallel to the regulatory challenges faced by psychedelics.

The profound impact of psychedelics is emphasized by their ability to induce long-lasting positive changes in mood, attitude, and behavior after just one or two doses, with some participants describing the experience as the "most personally meaningful and spiritually significant experience of their lives." This phenomenon is likened to an "inverse PTSD effect," suggesting a potential for beneficial brain rewiring that could offer a paradigm shift in mental health treatment. The episode concludes with a hopeful outlook for the eventual approval and widespread availability of these treatments, especially in light of increasing psychiatric effects from global events like the COVID-19 pandemic, anticipating a rapid and long-lasting positive impact.

Psychedelics activate the serotonin 5HT2a receptor in the brain, antidepressants and the atypical anti-psychotics also affect this receptor but in different ways.

Psychedelics or a class of drugs that cause hallucination experiences and altered states of consciousness, when you consume a normal dose of them.

Ketamine causes altered states of consciousness and hallucinatory experiences but the effect is very temporary lasting maybe hours on average. So it's not included in the list of classic psychedelics.

Currently psilocybin is a schedule one drug which means that it's illegal to use and possess. It can only be used for research purposes.

Breakthrough therapy designation means that the approval process will be shortened and fast tracked.

Psilocybin behaves like no other medication treatment we have after one or two doses, people in the studies reported positive changes in mood, attitude and behavior that lasts months, to years.

In a 2008 study, many people reported 14 months later that the psilocybin was the most personally meaningful and spiritually significant experience of their lives. That's profound.

Some people have referred to the treatment with psychedelics as having an inverse PTSD effect.

With PTSD, you have a single exposure or something traumatic that has long lasting negative mental effects because of the way the experience rewires your brain.

Similarly, the psychedelics or with the psychedelics, one dose has shown to have long lasting positive effects on your worldview, your attitude, mood, and behavior.

The only way around this is to participate in the trials if there is one in your area, and if you're eligible.

I'm hopeful that as we see more long-term psychiatric effects of COVID infection and pandemic effects, that this drug will get approved and make a world of difference very quickly with long lasting impact.